Table 1 Comparison of characteristics between hypoglycemia and non-hypoglycemia groups.
From: Predictive factors of hypoglycemia in type 2 diabetes: a prospective study using machine learning
Variables | Non-hypoglycemia (n = 887) | Hypoglycemia (n = 419) | P value |
|---|---|---|---|
Age, years | 61 [55–68] | 64 [58–71] | < 0.001 |
Male, n (%) | 454 (51.2%) | 176 (42.0%) | 0.32 |
Diabetes duration, years | 11 [6–15.42] | 16.12 [13–21] | < 0.001 |
Insulin therapy, n (%) | 208 (22.8%) | 342 (86.1%) | < 0.001 |
BMI, kg/m2 | 28.04 [25.3–31.23] | 28.26 [25.29–31.99] | 0.139 |
HbA1C, mg/dl | 7.33 [7–8.2] | 8 [7–8.1] | 0.024 |
Total cholesterol, mg/dl | 149 [126–178] | 144 [122–165] | < 0.001 |
Triglycerides, mg/dl | 138 [106–181]] | 130 [97–168] | < 0.001 |
eGRF, mL/min/1.73 m2 | 70 [60.97–84.78] | 62.45 [49.84–74.35] | < 0.001 |
Antidiabetic drug therapy | |||
IIT with SGLT2 inhibitors, DPP-4 inhibitors, or biguanide, n (%) | 151 (17%) | (173) 41.2% | < 0.001 |
Basal insulin with SGLT2 inhibitors, DPP-4 inhibitors, or biguanide, n (%) | 144 (16.2%) | 93 (22.1%) | 0.36 |
IIT with sulfonylureas, n (%) | 0 | 20 (4.7%) | 0.08 |
Sulfonylureas with biguanide, or SGLT2 inhibitors, n (%) | 98 (11%) | 133 (31.7%) | < 0.001 |
DPP-4 inhibitors with biguanide, n (%) | 88 (9.9%) | 0 | 0.003 |
SGLT2 inhibitors with biguanide, n (%) | 407 (45.8%) | 0 | < 0.001 |
